Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: cerebrovascular
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Acute Ischemic Stroke
- Interventions
- Semaglutide 0.5 mg; Normal Saline
- Conditions
- Acute Ischemic Stroke
- Phase and size
- Phase 3 · 436 participants
- Dates
- Start 2025-07-01
Primary completion 2027-07-31 - Sponsor
- RenJi Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- mRS at 90-days90 days postoperatively
02Eligibility
Who can take part
Inclusion Criteria: 1. Clinical or imaging diagnosis of acute ischemic stroke within 24 hours after onset; 2. Scheduled for endovascular thrombectomy; 3. Age ≥18 years; 4. Pre-stroke modified Rankin Scale (mRS) score ≤1; 5. Informed consent voluntarily signed by the patient or legal representative. Exclusion Criteria: 1. Preoperative imaging diagnosis of intracranial hemorrhage, or history of intracranial hemorrhage within 3 months prior to surgery; 2. Contraindications for endovascular thrombectomy; 3. Recent history of ischemic stroke; 4. Fasting blood glucose \<3.9 mmol/L; 5. ASA classification of IV-V; 6. Severe organic heart disease or severe arrhythmia; 7. Pregnant or lactating women; 8. Contraindications to semaglutide or allergy to semaglutide.
03Change log
Registry changes
No changes recorded since the trial was added.